Early Life Vaccination: Generation of Adult-quality Memory CD8+ T Cells in Infant Mice Using Non-replicating Adenoviral Vectors
Authors
Affiliations
Intracellular pathogens represent a serious threat during early life. Importantly, even though the immune system of newborns may be characterized as developmentally immature, with a propensity to develop Th2 immunity, significant CD8+ T-cell responses may still be elicited in the context of optimal priming. Replication deficient adenoviral vectors have been demonstrated to induce potent CD8+ T-cell response in mice, primates and humans. The aim of the present study was therefore to assess whether replication-deficient adenovectors could overcome the risk of overwhelming antigen stimulation during the first period of life and provide a pertinent alternative in infant vaccinology. To address this, infant mice were vaccinated with three different adenoviral vectors and the CD8+ T-cell response after early life vaccination was explored. We assessed the frequency, polyfunctionality and in vivo cytotoxicity of the elicited memory CD8+ T cells, as well as the potential of these cells to respond to secondary infections and confer protection. We further tested the impact of maternal immunity against our replication-deficient adenoviral vector during early life vaccination. Overall, our results indicate that memory CD8+ T cells induced by adenoviral vectors in infant mice are of good quality and match those elicited in the adult host.
Chauhan N, Soni S, Gupta A, Aslam M, Jain U J Med Virol. 2020; 93(4):1967-1982.
PMID: 33270225 PMC: 7753271. DOI: 10.1002/jmv.26709.
Benest J, Rhodes S, Afrough S, Evans T, White R Vaccines (Basel). 2020; 8(2).
PMID: 32235634 PMC: 7349762. DOI: 10.3390/vaccines8020155.
Afrough S, Rhodes S, Evans T, White R, Benest J Vaccines (Basel). 2020; 8(1).
PMID: 32192058 PMC: 7157626. DOI: 10.3390/vaccines8010131.
Neutrophil extracellular traps (NETs) exacerbate severity of infant sepsis.
Colon D, Wanderley C, Franchin M, Silva C, Hiroki C, Castanheira F Crit Care. 2019; 23(1):113.
PMID: 30961634 PMC: 6454713. DOI: 10.1186/s13054-019-2407-8.
Future Prospects for the Development of Cost-Effective Adenovirus Vaccines.
Fougeroux C, Holst P Int J Mol Sci. 2017; 18(4).
PMID: 28420073 PMC: 5412272. DOI: 10.3390/ijms18040686.